<DOC>
	<DOCNO>NCT00006457</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development cancer . PURPOSE : Randomized phase I trial study effectiveness oltipraz prevent lung cancer people smoke .</brief_summary>
	<brief_title>Oltipraz Prevention Lung Cancer People Who Smoke</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect oltipraz level BP-7,8-diol-9,10-epoxide ( BPDE ) DNA adduct lung line cell ( macrophage bronchial epithelial cell ) smoker . - Determine tolerability toxicity treatment regimen patient . - Determine effect treatment regimen level macromolecule adduct blood ( e.g. , BPDE DNA , BPDE hemoglobin , 8-hydroxy-deoxyguanine ) , oral lining cell ( BPDE DNA ) , bladder lining cell ( 4-aminobiphenyl DNA ) , lung macrophage ( 8-hydroxy-deoxyguanine ) patient . - Determine effect treatment regimen change ( decrease ) activation NNK measure change ( increase ) urinary NNAL plus NNAL glucuronide patient . - Determine effect treatment regimen oxidative state , glutathione-S-transferase activity , superoxide dismutase 3 phase II enzymes lung blood patient . - Compare change oxidative state phase II enzymes change adduct level lung blood patient . - Determine correlation oltipraz-induced change phase II enzyme adduct formation genotypic variation glutathione-S-transferase isozymes patient . - Compare response treatment regimen term oxidative state , phase II enzymes , adduct formation lung vs blood patient . OUTLINE : This randomize , double-blind , multicenter study . Patients stratify accord participate center . Patients randomize one three treatment arm . - Arm I : Patients receive oral placebo weekly . - Arm II : Patients receive low-dose oral oltipraz weekly . - Arm III : Patients receive high-dose oral oltipraz weekly . Treatment continue 12 week absence unacceptable toxicity . Patients follow 4 week . PROJECTED ACCRUAL : A total 66 patient ( 22 per treatment arm ) accrue study within 21 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Oltipraz</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Current cigarette smoker At least 20 cigarette day No variation 10 number cigarette smoke per day within past 3 month At least 10 year smoke amount Failed stop smoking least one attempt quit within last 3 year Prior stage I nonsmall cell lung cancer allow surgically resect least lobectomy No concurrent evidence lung cancer Willing undergo 2 bronchoscopies PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 0 Life expectancy : Not specify Hematopoietic : CBC normal Hemostasis normal Hepatic : PT PTT normal Renal : Blood chemistry normal Nonfasting glucose great 200 mg/dL No active renal disease No urinary tract infection urinalysis ( trace protein allow ) Cardiovascular : EKG normal No coronary artery disease require continuous medication Pulmonary : Chest radiograph normal ( postsurgical change allow ) No acute significant chronic abnormality FEV1 great 1.8 L 75 % predict No chronic obstructive pulmonary disease require continuous medication Other : No known hypersensitivity prior adverse reaction oltipraz No inmate prisoners No medical psychological condition would preclude study ( e.g. , acute psychosis ) No prior malignancy except nonmelanomatous skin cancer , cervical dysplasia , curatively treated stage I II cancer head neck Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 month since prior potential chemoprevention agent ( e.g. , oltipraz , retinoids , acetylcysteine ) Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>small cell lung cancer</keyword>
</DOC>